Biogen (BIIB) return on invested capital (ROIC)

Return on invested capital · fiscal 2025
9.8%

Biogen (BIIB) earned a return on invested capital of 9.8% in fiscal 2025 (the year ended December 31, 2025). That is 0.4 percentage points higher than the 9.3% of fiscal 2024. Figures as of 18 Nov 2026, 00:40 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on invested capital, fiscal 2025
9.8%
Change on fiscal 2024
+0.4 pts
Highest on record
15.8%fiscal 2022
Lowest on record
7.8%fiscal 2023
Fiscal years on record
42022–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Biogen return on invested capital (ROIC), in more detail

Across the 4 fiscal years on record (2022–2025), the highest was 15.8% in fiscal 2022 and the lowest 7.8% in fiscal 2023. The fiscal 2025 figure is higher than in 67% of the 3 earlier fiscal years on record, whose median is 9.3%.

History · 4 fiscal years

Return on invested capital by fiscal year

Biogen return on invested capital (ROIC), year by year

Biogen (BIIB) return on invested capital (ROIC) by fiscal year
Fiscal yearReturn on invested capitalChangeYear ended
20259.8% 0.4 pts up
20249.3% 1.5 pts up
20237.8% 8.0 pts down
202215.8%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on invested capital is operating income after tax divided by the capital in the business — debt plus equity minus cash — using the company's own tax rate where it is plausible and 21% otherwise, and shown only for the fiscal years in which cash is counted one way.

How to read it

It measures how well the business turns capital into profit whoever supplied it; a figure above the cost of that capital, roughly 8–10%, means growth creates value.

Return on invested capital at health care companies of similar size

Return on invested capital of Biogen and comparable companies
CompanyReturn on invested capitalFiscal year
Royalty Pharma RPRX8.8%2025
Biogen BIIB9.8%2025
GE HealthCare Technologies GEHC13.1%2025
Alcon ALC4.5%2025
Mettler-Toledo International MTD45.0%2025
Centene CNC-1.4%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on BIIB

Biogen, figure by figure

Biogen (BIIB) overview: price, valuation and scorecardAll health care companies by market value

Biogen return on invested capital (ROIC): questions and answers

What is Biogen's return on invested capital?

Biogen (BIIB) earned a return on invested capital of 9.8% in fiscal 2025 (the year ended December 31, 2025). That is 0.4 percentage points higher than the 9.3% of fiscal 2024.

Is Biogen's return on invested capital high or low compared with its own history?

The fiscal 2025 figure is higher than in 67% of the 3 earlier fiscal years on record, whose median is 9.3%.

What are the highest and lowest return on invested capital figures on record for Biogen?

Across the 4 fiscal years on record (2022–2025), the highest was 15.8% in fiscal 2022 and the lowest 7.8% in fiscal 2023.

How is Biogen's return on invested capital calculated?

Return on invested capital is operating income after tax divided by the capital in the business — debt plus equity minus cash — using the company's own tax rate where it is plausible and 21% otherwise, and shown only for the fiscal years in which cash is counted one way.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Biogen (BIIB) return on invested capital (ROIC)”, data as of 18 November 2026. https://funkfolio.com/stock/BIIB/roic

Underlying data: the company's filings with the SEC and Yahoo Finance.